Could a simple shot replace hospital stays for myeloma patients?

This study tests whether the drug elranatamab can be given safely in an outpatient clinic instead of the hospital for people with multiple myeloma that has come back or stopped responding to treatment. About 46 adults will receive the drug along with a single preventive dose of another medicine to lower the risk of a common side effect called cytokine release syndrome. The main goal is to see how many patients experience this side effect during the first treatment cycle.